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Background: The objective of this study was to forecast the impact of COVID-19 vaccination in 
the United States (US) and China, two countries at different epidemic phases.  
Methods: A mathematical model describing SARS-CoV-2 transmission and disease progression 
was used to investigate vaccine impact. Impact was assessed both for a vaccine that prevents 
infection ( 95%SVE = ) and a vaccine that prevents only disease ( 95%PVE = ).  
Results: For 95%SVE =  and gradual easing of restrictions, vaccination in the US reduced the 
peak incidence of infection, disease, and death by >55% and cumulative incidence by >32%, and 
in China by >77% and >65%, respectively. Nearly three vaccinations were needed to avert one 
infection in the US, but only one was needed in China. For 95%PVE = , benefits of vaccination 
were half those for 95%SVE = . In both countries, the impact of vaccination was substantially 
enhanced with rapid scale-up, vaccine coverage >50%, and slower or no easing of restrictions, 
particularly in the US.    
Conclusions: COVID-19 vaccination can flatten, delay, and/or prevent future epidemic waves. 
However, vaccine impact is destined to be heterogeneous across countries because of an 
underlying “epidemiologic inequity” that reduces benefits for countries already at high 
incidence, such as the US. Despite 95% efficacy, actual vaccine impact could be meager in such 
countries, if vaccine scale-up is slow, acceptance of the vaccine is poor, or restrictions are eased 
prematurely.  
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With over 80 million infections and a death toll approaching two million [1], the severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has been one of the most 
challenging global health emergencies in recent history [2]. The unparalleled burden on 
healthcare systems has necessitated unprecedented restrictions on mobility and on social and 
economic activities [3,4]. The ensuing losses to national and global economies are probably the 
largest since the Great Depression [2,5]. 
We previously developed a mathematical model to investigate the generic population-level 
impact of SARS-CoV-2 vaccination [6]. In light of recently produced vaccines with ~95% 
efficacy against Coronavirus Disease 2019 (COVID-19) symptomatic disease [7,8], the model 
was extended to assess the impact of these novel vaccines on COVID-19 morbidity and mortality 
in two major countries at different epidemic phases, the United States (US) and China. The 
impact was assessed under two different assumptions for the mechanism of action of the vaccine, 
that it prevents both infection and disease, or that it prevents only disease. The impact was 
further assessed at different levels of vaccine coverage, different time courses for vaccine scale-
up, and different schedules for easing of social and physical distancing restrictions, following the 
launch of vaccination.  
Materials and Methods 
Mathematical model and parameterization 
The extended model was age-structured, stratifying the population into cohorts based on 
vaccination status, age group, infection status, infection stage, and disease stage. Population 
movement among cohorts was determined using a set of coupled nonlinear differential equations. 
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Given interest in assessing vaccination impact in the short-term (over only 2021), demography 
was assumed stable. Contact between individuals in different age groups was determined using 
an age-mixing matrix that allowed a range of assortativeness in mixing. Details of the model are 
in Supplementary Information Texts S1A-S1B and Figures S1-S2. The model was coded, fitted, 
and analyzed using MATLAB R2019a [9]. 
Since the evidence suggests that reinfection with this virus is a rare event [10-14], those 
recovered from infection were assumed protected against reinfection, but only for one year, 
based on the behavior of other “common cold” coronaviruses [15]. For the same purpose, it was 
assumed that vaccine-induced immunity will also last for only one year. The waning of both 
natural and vaccine immunity was assumed to follow a gamma distribution of order 15n = . That 
is, most people lose their immunity after about one year, and only a small minority lose their 
immunity after a period that is either much shorter or much longer than one year (Figure S3).  
The model was parameterized using state-of-the-art empirical evidence for the infection’s natural 
history and epidemiology. The distribution of infected individuals across the mild (or 
asymptomatic), severe, or critical infection stages and the infection mortality rate in each age 
group were based on the analyzed epidemic of France [16]. All age groups were assumed 
(biologically) equally susceptible to this infection. Population demographic information (size, 
age distribution, and life expectancy) were obtained from the United Nations World Population 
Prospects database [17]. Details of model parameters, values, and justifications are in 
Supplementary Information Text S1C and Tables S1-S2. 
Characteristics of the vaccine and scale-up scenarios 
Since the primary endpoint of the vaccine’s randomized clinical trials was efficacy of the vaccine 
against laboratory-confirmed COVID-19 cases [7,8,18], and not just any infection, documented 
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or undocumented, it is unknown whether the vaccine prophylactically reduces susceptibility to 
the infection (that is, 
SVE  efficacy defined as the proportional reduction in the susceptibility to 
infection among those vaccinated, compared to those unvaccinated [6]), or whether it just 
reduced serious symptomatic COVID-19 cases with no effect on infection (that is, PVE  efficacy 
against disease progression, defined as the proportional reduction in the fraction of individuals 
with severe or critical infection among those vaccinated, but who still acquired the infection, 
compared to those unvaccinated [6]). These two mechanisms of action bracket the two extremes 
for the vaccine’s biological effect, with the former mechanism being the most optimistic 
(reducing both infection and disease) and the latter being the most pessimistic (reducing only 
disease). 
Notwithstanding this uncertainty, the impact of the vaccine was assessed under each of these 
mechanisms of action, assuming 95%SVE =  or 95%PVE = . In the baseline scenario, the 
vaccine was introduced in both countries on January 1, 2021 with a scale-up to reach vaccine 
coverage of 80% by the end of 2021. Given that the purpose of vaccination is to alleviate the 
need for restrictions that have stifled social and economic activities, social distancing restrictions 
were assumed to be eased gradually over six months, so that “normalcy” would be attained at the 
end of these six months. Normalcy was defined as a social contact rate in the population equal to 
that prior to the pandemic. 
Since the US has experienced a large epidemic, it was assumed that 20% of the US population 
has already been infected by January 1, 2021, with those already infected (if subsequently 
vaccinated) not benefiting from the immunity conferred by this vaccine. Moreover, the basic 
reproduction number at time of onset of vaccination was assumed at 0 1.2R = , reflecting the 
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current phase of an expanding epidemic. It was also assumed that 
0R  will gradually increase 
with easing of restrictions to reach 0 4R =  at the end of six months. The value of 0 4R =  is 
justified by existing estimates assuming a “natural” epidemic in the absence of interventions 
[19,20].  
For China, it was assumed that the entire population is still susceptible to the infection, given the 
small number of documented infections relative to its large population size, and that the 
epidemic was contained [1,21]. Moreover, it was assumed that 0 1R =  at the onset of vaccination 
(reflecting the non-expanding epidemic), but that 0R  will gradually increase with easing of 
restrictions to reach an 0 4R =  at the end of six months.  
Measures of vaccine impact  
The population-level impact of SARS-CoV-2 vaccination was assessed by quantifying incidence, 
cumulative incidence, and reduction in incidence of infections, severe disease cases, critical 
disease cases, and COVID-19 deaths arising in the presence of vaccination compared to the 
counter-factual scenario of no-vaccination. Vaccine effectiveness, that is number of vaccinations 
needed to avert one infection or one adverse disease outcome (ratio of the number of 
vaccinations relative to the number of averted outcomes) was further calculated to inform future 
cost-effectiveness analyses. 
Uncertainty analysis 
A multivariable uncertainty analysis was conducted to determine the range of uncertainty for 
model predictions using five-hundred model runs. At each run, Latin Hypercube sampling 
[22,23] was applied to select vaccine efficacy from within its reported credible range [8], and to 
select a vaccine duration of protection within ±30% of one-year duration. The resulting 
All rights reserved. No reuse allowed without permission. 
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 
The copyright holder for this preprintthis version posted January 8, 2021. ; https://doi.org/10.1101/2021.01.07.21249380doi: medRxiv preprint 
7 
 
distribution for vaccine impact across all 500 runs was used to calculate the predicted means of 
different outcomes and the uncertainty associated with those means. 
Results 
For 95%SVE = , vaccination in the US flattened the epidemic curve, but did not prevent a new 
epidemic wave, though it resulted in a smaller one, with the assumed gradual easing of 
restrictions following the onset of vaccination (Figure 1). The vaccine reduced peak incidence of 
infection, severe disease, critical disease, and COVID-19 death by 59.6%, 59.5%, 59.0%, and 
55.3%, respectively, and the cumulative number of infections, severe disease cases, critical 
disease cases, and deaths by 35.7%, 35.2%, 35.0%, and 32.7%, respectively, by end of 2021. 
However, incidence started to increase toward the end of 2021, as vaccine immunity waned and 
those previously infected began losing their protective immunity against reinfection.  
For 95%PVE = , the vaccination had no impact on infection (as it does not protect against 
infection) and less impact on disease and death (Figure S4). Peak incidence of severe disease, 
critical disease, and death was reduced by only 22.0%, 22.0%, and 21.1%, respectively. The 
cumulative number of severe disease cases, critical disease cases, and deaths were reduced by 
only 17.4%, 17.2%, and 16.7%, respectively, by end of 2021.  
In China, the impact of vaccination was larger than in the US, as the vaccine was introduced at a 
time when disease incidence was negligible. For 95%SVE = , vaccination not only flattened the 
epidemic curve, but also delayed it by a few months (Figure 2). The vaccine reduced peak 
incidence of infection, severe disease, critical disease, and death by 85.6%, 84.2%, 84.3%, and 
77.3%, respectively, and the cumulative number of infections, severe disease cases, critical 
disease cases, and deaths by 65.7%, 65.0%, 65.3%, and 65.3%, respectively, by end of 2021.  
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For 95%PVE = , the vaccination had less impact on disease and death (Figure S5). Peak 
incidence of severe disease, critical disease, and death was reduced by 44.5% for all of these 
indicators, as well as for their cumulative numbers. 
In the US, for 95%SVE = , the cumulative number of averted disease cases increased steadily in 
response to shorter scale-up (to 80% coverage) (Figure 3A). However, in China, there was no 
additional benefit to be had by shortening scale-up to less than 8 months, as the epidemic was 
fully contained (Figure 3C). Similar results were obtained for 95%PVE = , as shown for the US 
and China (Figures S6A and S6C), respectively. 
For 95%SVE = , the cumulative number of averted disease cases increased steadily with higher 
vaccine coverage (by end of 2021) in both countries (Figures 3B and 3D). The gains in averted 
disease cases increased sharply as vaccine coverage exceeded 70% in the US and 50% in China, 
because such coverage prevented a much larger epidemic wave. Similar results were obtained for 
95%PVE = , in both the US and China (Figures S6B and S6D, respectively). 
In the US, for 95%SVE = , the effectiveness of the vaccine in preventing infection (Figure 4A), 
severe disease (Figure 4B), critical disease (Figure 4C), and death (Figure 4D), was substantially 
enhanced by more rapid scale-up to reach 80% coverage, since the epidemic was already at high 
incidence at time vaccination was launched. Whereas in the US, only one vaccination was 
needed to avert one infection, provided that scale-up could be accomplished in 6 months, nearly 
3 vaccinations were needed to avert one infection if the scale-up required 12 months. This, 
however, was not the case in China (Figure S7). Regardless of the speed of scale-up, only one 
vaccination was needed to avert one infection.  
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Figure 5 shows a comparison of the impact of vaccine scale-up duration on the number of 
vaccinations needed to avert one severe disease case (Figure 5A), one critical disease case 
(Figure 5B), and one death (Figure 5C), in the US, between the assumption of 95%SVE =  and 
that of 95%PVE = . As expected, a vaccine that prevents infection (and consequently disease) 
was superior to a vaccine preventing only disease. That superiority was even greater if scale-up 
is longer, where twice as many vaccinations were needed to avert each of these outcomes. 
Similar results were obtained for China (Figure S8).  
In all of the above scenarios, it was assumed that easing of social restrictions would occur during 
six months following initiation of vaccination. However, as expected, a longer duration for 
easing restrictions resulted in a more favorable impact of vaccination, in both the US and China 
(Figure S9).  
Uncertainty regarding the projected impact was small in the short-term for the US and China, in 
the first wave after vaccinations commenced, but it was large toward the end of 2021, as 
expected, due to uncertainty about persistence of the vaccine’s protective immunity (Figure S10).  
Discussion  
The key conceptual finding that emerges from this study is that vaccine impact is strongly 
dependent on the difference between two essential metrics, “time to infection” and “time to 
vaccination.” The competing “hazard” dynamics between the event of infection and the event of 
vaccination explain the variability of impact under the parameters considered: incidence at the 
onset of vaccination, duration of scale-up, vaccine coverage, or timing of the easing of 
restrictions. As the average time to vaccination is shortened relative to the average time to 
infection, by altering these parameters (by more rapid scale-up, slower easing of restrictions, or 
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reducing infection incidence through lockdowns or other restrictive measures), the impact would 
be more favorable, and fewer vaccinations would be needed to avert one infection or disease 
outcome.    
A striking demonstration of this concept’s importance can be seen in the case of a vaccine that 
does not prevent infection, but prevents disease with 95%PVE =  (Figures S4 and S5). This 
vaccine would not affect the time to infection in the population, and any easing of restrictions 
with vaccination will shorten the time to infection. Accordingly, such a vaccine, despite its 95% 
efficacy, would end up averting <20% of disease cases and deaths in the US and <50% in China. 
Since the time to infection in the US is much shorter than in China, as a consequence of the 
current high incidence rate, vaccine impact will be more favorable in China, where vaccination 
can be scaled up over a longer duration and still have superior impact to that in the US.  
A consequence of the above findings is that vaccine impact will likely be heterogenous among 
nations. Countries with low or negligible incidence will benefit most from vaccination. Vaccine 
cost-effectiveness will be also optimized in such countries, with only one vaccination needed to 
avert one infection for a vaccine with 95%SVE = (Figure S7).      
Several other findings emerged from this study. Vaccination will flatten the epidemic curve, but 
may not prevent (or delay) a new wave, unless it is scaled up very rapidly (Figures 1-3). There is 
every virtue in rapidly scaling up vaccination, particularly in countries already suffering 
substantial incidence (Figure 3). Importantly, vaccination impact does not increase linearly with 
vaccine coverage—gains from vaccination would be proportionally higher if vaccine coverage 
exceeds 50% (Figure 3), stressing the importance of reaching high vaccine coverage. Easing of 
restrictions concurrently with vaccination can undermine many benefits of vaccination, as more 
people are likely to become infected before they are vaccinated. Easing of restrictions needs to 
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be slow and gradual, tailored to the epidemiologic situation in each country (Figure S9). For 
instance, with its ongoing high incidence, easing of restrictions is not warranted in the US, while 
vaccination is scaled up. 
With 95% efficacy, COVID-19 vaccination is very cost-effective, as fewer than 3 vaccinations 
are needed to avert one infection, and this effectiveness can be optimized further with more rapid 
scale-up (Figure 4 and Figure S7). The impact of vaccination in averting disease or death is two-
fold higher for a vaccine that prevents infection, compared to a vaccine that only prevents 
disease (Figures 1-2 versus Figures S4-S5). This is because preventing infection not only 
prevents disease directly, but also reduces infection circulation; thus, also indirectly reducing 
disease. Moreover, twice as many vaccinations are needed to avert one disease or death outcome 
for a vaccine that prevents only disease, compared to one that prevents infection (Figure 5 and 
Figure S8).         
This study has some limitations. Model estimations are contingent on the validity and 
generalizability of input data. While we used available evidence for SARS-CoV-2 natural history 
and epidemiology, our understanding of its epidemiology is still evolving. All age groups were 
assumed equally susceptible to infection, but evidence suggests some biological differences in 
susceptibility [24-31]. The exact extent of exposure to the infection in both the US and China is 
unknown, but plays an important role in vaccine impact. From an epidemiological perspective, 
we assumed that 20% of the US population and a negligible percentage of the Chinese 
population have been already infected, but vaccine impact can be quite different if such 
assumptions prove unrealistic. Vaccinated persons were assumed to be immediately protected, 
once vaccinated, but in reality, vaccine protection develops over the course of a month following 
inoculation [7,8]. Two parameters remain unknown, despite being critical to the longer-term 
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impact of vaccination: durations of vaccine protection and natural immunity. If both prove to be 
relatively brief, the impact of the vaccine will be diminished and it may be necessary to 
periodically re-immunize, or to develop additional vaccines that protect against other circulating 
strains of this virus. 
Conclusions 
COVID-19 vaccination can have an immense impact on averting infection and/or disease. It can 
substantially flatten and delay future epidemic waves (if not prevent them altogether), and will 
be highly cost-effective, given the small number of vaccinations needed to avert one infection or 
one disease outcome. However, the impact of vaccination is likely to vary among countries, 
reflecting an underlying “epidemiological inequity”, as the epidemic phase in those countries 
also varies. Nations that will benefit most from vaccination are those where waiting time before 
vaccination is much shorter than time to infection, that is countries currently at low incidence, 
such as China. For countries at high incidence, the impact may prove far less than current 
expectations, despite the vaccine’s 95% efficacy, if vaccination is scaled up slowly and/or if 
restrictions are eased prematurely. For countries such as the US, there is every virtue in scaling 
up vaccination rapidly, reaching high vaccine coverage, and delaying any easing of restrictions 
until viral incidence reaches low levels.         
All rights reserved. No reuse allowed without permission. 
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 
The copyright holder for this preprintthis version posted January 8, 2021. ; https://doi.org/10.1101/2021.01.07.21249380doi: medRxiv preprint 
13 
 
Figure 1. Impact of SARS-CoV-2 vaccination on numbers of A) new infections, B) new 
severe disease cases, C) new critical disease cases, and D) new deaths in the United States. 
The vaccine is assumed to have an efficacy of 95% against infection and is introduced on 
January 1, 2021, when the proportion of the population already infected is 20%. Vaccine 
coverage is scaled up to reach 80% by December 31, 2021. Duration of both vaccine protection 
and natural immunity is one year. This scenario assumes an 0R  of 1.2 on January 1, 2021, which 
increases with gradual easing of restrictions to reach 4.0 after six months. Results of a scenario 
assuming that the vaccine has no efficacy against infection, but an efficacy of 95% against severe 
and critical disease are shown in Figure S4. 
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Figure 2. Impact of SARS-CoV-2 vaccination on numbers of A) new infections, B) new 
severe disease cases, C) new critical disease cases, and D) new deaths in China. The vaccine 
is assumed to have an efficacy of 95% against infection and is introduced on January 1, 2021. 
Vaccine coverage is scaled up to reach 80% by December 31, 2021. Duration of both vaccine 
protection and natural immunity is one year. This scenario assumes an 
0R  of 1.0 on January 1, 
2021, which increases with gradual easing of restrictions, to reach 4.0 after six months. Results 
of a scenario assuming that the vaccine has no efficacy against infection, but an efficacy of 95% 
against severe and critical disease are shown in Figure S5. 
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Figure 3. Impact of vaccine scale-up duration and vaccine coverage on numbers of averted 
severe and critical disease cases for a vaccine that protects against both infection and 
disease. Cumulative averted severe and critical disease cases in A) the United States and C) 
China at different vaccination scale-up durations to reach 80% coverage. Cumulative averted 
severe and critical disease cases in B) the United States and D) China at varying levels of 
vaccine coverage. The vaccine is assumed to have an efficacy of 95% against infection and is 
introduced on January 1, 2021, when the cumulative proportion of the population infected is 20% 
in the United States and 0% in China. Duration of both vaccine protection and natural immunity 
is one year. This scenario assumes gradual easing of restrictions within 6 months. The results of 
a scenario assuming the vaccine has no efficacy against infection, but an efficacy of 95% against 
severe and critical disease is shown in Figure S6. 
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Figure 4. Impact of vaccine scale-up duration on the number of vaccinations needed to 
avert one infection (A), one severe disease case (B), one critical disease case (C), and one 
death (D) in the United States. The vaccine is assumed to have an efficacy of 95% against 
infection and is introduced on January 1, 2021, when the cumulative proportion of the population 
infected is 20%. Duration of both vaccine protection and natural immunity is one year. This 
scenario assumes a gradual easing of restrictions within 6 months. Corresponding results for 
China are shown in Figure S7. 
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Figure 5. Comparison of the impact of a vaccine acting against infection (VES efficacy) 
versus a vaccine acting only against disease (VEP efficacy) in the United States. The number 
of vaccinations needed to avert one severe disease case (A), one critical disease case (B), and one 
death (C), for a vaccine with 95%SVE =  versus a vaccine with 95%PVE = . The vaccine is 
introduced on January 1, 2021, when the cumulative proportion of the population infected is 
20%. Duration of both vaccine protection and natural immunity is one year. This scenario 
assumes a gradual easing of restrictions within 6 months. Corresponding results for China are 
shown in Figure S8. 
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Text S1. SARS-CoV-2 vaccine mathematical model 
A. Model structure 
We extended a recently-developed age-structured deterministic compartmental model [1-5] to 
describe the impact of vaccination on the severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) transmission dynamics and progression of the resulting disease, Coronavirus 
Disease 2019 (COVID-2019), in a given population. The model stratifies the unvaccinated and 
vaccinated populations into compartments according to age group (0-9, 10-19, 20-29,…, ≥80 
years), infection status (uninfected, infected), infection stage (mild, severe, critical), disease 
stage (severe, critical), and compartments for the gamma distribution (Γ-distribution) describing 
the waning of natural and vaccine immunity. 
Transmission and disease progression dynamics in the vaccinated and unvaccinated cohorts are 
described in the model using age-specific sets of nonlinear ordinary differential equations, where 
each age group a  ( 1,2,...9a = ) refers to a 10-year age band (0-9,10-19,..70-79) apart from the 
last group including all those aged ≥0 years. The model is illustrated in Figure S1. 
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Figure S1. Schematic diagram describing the SARS-CoV-2 transmission dynamics model in presence of a vaccine that reduces 
susceptibility to infection. 
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Where n  stands for the order of the gamma distribution (Γ-distribution) describing waning of 
natural or vaccine immunity. 
The definitions of population variables and symbols used in the equations are in Table S1. 
Table S1. Definitions of population variables and symbols used in the model. 
Symbol Definition 
Transmission dynamics parameters 
( )S a  Unvaccinated susceptible population 
( )E a  Unvaccinated latently infected population 
( )MI a  Unvaccinated population with asymptomatic or mild infection 
( )SI a  Unvaccinated population with severe infection 
( )CI a  Unvaccinated population with critical infection 
( )SD a  Unvaccinated population with severe disease 
( )CD a  Unvaccinated population with critical disease 
( )iR a  
thi  compartment to generate the gamma distribution for the waning of natural immunity 
among the unvaccinated recovered population 
( )iV a  
thi  compartment to generate the gamma distribution for the waning of vaccine immunity 
among the vaccinated susceptible population 
( )VE a  Vaccinated latently infected population 
( )VMI a  Vaccinated population with asymptomatic or mild infection 
( )VSI a  Vaccinated population with severe infection 
( )VCI a  Vaccinated population with critical infection 
( )VSD a  Vaccinated population with severe disease 
( )VCD a  Vaccinated population with critical disease 
( )ViR a  
thi  compartment to generate the gamma distribution for the waning of natural immunity 
among the vaccinated recovered population 
N   Total population size 
agen   Number of age groups 
n   Order of the gamma distribution (Γ-distribution) describing waning of natural or vaccine 
immunity 
( )a  Transition rate from one age group to the next age group 
  Overall infectious contact rate 
1/  Duration of latent infection 
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1/ M  Duration of asymptomatic or mild infection 
1/ DS  Duration of severe infection infectiousness before isolation and/or hospitalization  
1/ S  Duration of severe disease following onset of severe disease  
1/ DC  Duration of critical infection infectiousness before isolation and/or hospitalization  
1/ C  Duration of critical disease following onset of critical disease  
1/
R
  Duration of natural immunity  
1/   Natural death rate 
( )a  Mortality rate in each age group  
( )Mf a  Proportion of infections that will progress to be mild or asymptomatic infections  
( )Sf a  Proportion of infections that will progress to be severe infections 
( )Cf a  Proportion of infections that will progress to be critical infections 
Key vaccine product characteristics 
sVE   Vaccine efficacy in reducing susceptibility 
PVE  Vaccine efficacy in reducing severe and critical disease 
1/   Duration of vaccine protection 
The force of infection (hazard rate of infection) experienced by the unvaccinated susceptible 
populations ( )S a  is given by 
( )





( ) ( ) ( )
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )
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M S C M S C
a a n
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i
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V V V V V V V
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i i
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S a E a I a I a I a D a D a R a





     + + + + +
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       + + + + + + + + 
 
 






while that experienced by the vaccinated susceptible populations ( )V a  is given by 
( ) ( ) ( )1V Sa VE a = −  
where   is the overall infectious contact rate. The mixing among the different age groups is 
dictated by the mixing matrix ,a aH . This matrix provides the probability that an individual in the 
a  age group will mix with an individual in the a  age group (regardless of vaccination status). 
The mixing matrix is given by  
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Here, ,a a   is the identity matrix.  0,1Agee   measures the degree of assortativeness in the mixing. 
At the extreme 0Agee = , the mixing is fully proportional. Meanwhile, at the other extreme, 
1Agee = , the mixing is fully assortative, that is individuals mix only with members in their own 
age group. 
B. Model adjustment for a vaccine that reduces only severe and critical disease 
The above model was adjusted to accommodate for a vaccine that has no effect on infection, but 
that reduces both severe and critical disease with an efficacy 
PVE . A schematic diagram of the 
adjusted model is provided in Figure S2.  
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Figure S2. Schematic diagram describing the SARS-CoV-2 transmission dynamics model in presence of a vaccine that reduces 
severe and critical disease, but does not prevent infection.  
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Figure S3. Time course of waning natural infection and vaccine immunity. Waning of 
natural infection and vaccine immunity was parametrized using a gamma distribution with order 
15n = . That is, most people lose their immunity after about one year and only a small minority 
lose it much sooner or much later than one year. 
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C. Parameter values 
The input parameters of the model were chosen based on current empirical data for SARS-CoV-
2 natural history and epidemiology. The parameter values are listed in Table S2. 
Table S2. Model assumptions in terms of parameter values 
Parameter Symbol Value Justification 
Duration of latent 
infection 
 
1/  3.69 days Based on existing estimate [6] and based 
on a median incubation period of 5.1 
days [7] adjusted by observed viral load 
among infected persons [8] and reported 





1/ DS ; 
1/ DC  
3.48 days Based on existing estimate [6] and based 
on observed time to recovery among 
persons with mild infection [6, 10] and 
observed viral load in infected persons 
[8, 9, 11]
 
Duration of severe 
disease following onset 
of severe disease  
1/ S  28 days Observed duration from onset of severe 




1/ C  42 days Observed duration from onset of critical 
disease to recovery [10] 
Life expectancy in US 
Life expectancy in China 
1/   
1/   
79.10 years 
76.47 years 
United Nations World Population 
Prospects database [12] 
Proportion of infections 
that will progress to be 
mild or asymptomatic 
infections  
( )Mf a  Determined from 
( ) ( ) ( ) 1M S Cf a f a f a+ + =   
Observed proportion of infections that 
eventually develop mild or 
asymptomatic in France [10, 13, 14] 
Proportion of infections 
that will progress to be 
infections that require 
hospitalization in acute 
care beds 
( )Sf a   The distribution and age dependence of 
asymptomatic/mild, severe, or critical 
infections was based on the modeled 
SARS-CoV-2 epidemic in France [15] 
 
  Age 0-19 years 1 SRRS f  1 0.1RRS =  Model-estimated relative risk of severe 
infection based on the SARS-CoV-2 
epidemic in France [15] 
  Age 20-29 years 2 SRRS f  2 0.5RRS =  Model-estimated relative risk of severe 
infection based on the SARS-CoV-2 
epidemic in France [15] 
  Age 30-39 years 
Sf  Reference category  
( Sf =0.01) 
Model-estimated based on fitting the 
SARS-CoV-2 epidemic in France [15] 
  Age 40-49 years 3 SRRS f  3 1.2RRS =  Model-estimated relative risk of severe 
infection based on the SARS-CoV-2 
epidemic in France [15] 
  Age 50-59 years 4 SRRS f  4 2.3RRS =  Model-estimated relative risk of severe 
infection based on the SARS-CoV-2 
epidemic in France [15] 
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  Age 60-69 years 5 SRRS f  5 4.5RRS =  Model-estimated relative risk of severe 
infection based on the SARS-CoV-2 
epidemic in France [15] 
  Age 70-79 years 6 SRRS f  6 7.8RRS =  Model-estimated relative risk of severe 
infection based on the SARS-CoV-2 
epidemic in France [15] 
  Age 80+ years 7 SRRS f  7 27.6RRS =  Model-estimated relative risk of severe 
infection based on the SARS-CoV-2 
epidemic in France [15] 
Proportion of infections 
that will progress to be 
critical infections 
( )Cf a   The distribution and age dependence of 
asymptomatic/mild, severe, or critical 
infections was based on the modeled 
SARS-CoV-2 epidemic in France [15]
 
  Age 0-19 years 1 CRRC f  1 0.21RRC =  Model-estimated relative risk of critical 
infection based on the SARS-CoV-2 
epidemic in France [15] 
  Age 20-29 years 2 CRRC f  2 0.33RRC =  Model-estimated relative risk of critical 
infection based on the SARS-CoV-2 
epidemic in France [15] 
  Age 30-39 years 
Cf  Reference category  
0.0002Cf =   
Model-estimated based on fitting the 
SARS-CoV-2 epidemic in France [15] 
  Age 40-49 years 3 CRRC f  3 1.83RRC =  Model-estimated relative risk of critical 
infection based on the SARS-CoV-2 
epidemic in France [15] 
  Age 50-59 years 4 CRRC f  4 4.67RRC =  Model-estimated relative risk of critical 
infection based on the SARS-CoV-2 
epidemic in France [15] 
  Age 50-59 years 4 CRRC f  4 4.67RRC =  Model-estimated relative risk of critical 
infection based on the SARS-CoV-2 
epidemic in France [15] 
  Age 60-69 years 5 CRRC f  5 10.58RRC =  Model-estimated relative risk of critical 
infection based on the SARS-CoV-2 
epidemic in France [15] 
  Age 70-79 years 6 CRRC f  6 13.61RRC =  Model-estimated relative risk of critical 
infection based on the SARS-CoV-2 
epidemic in France [15] 
 7 CRRC f  7 8.67RRC =  Model-estimated relative risk of critical 
infection based on the SARS-CoV-2 
epidemic in France [15] 
Disease mortality rate in 
each age group 
( )a   The distribution and age dependence of 
COVID-19 mortality was based on the 
modeled SARS-CoV-2 epidemic in 
France [15]
 
  Age 0-19 years 1RRD   1 0.10RRD =  Model-estimated relative risk of death 
based on the SARS-CoV-2 epidemic in 
France [15]
 
  Age 20-29 years 2RRD   2 0.40RRD =  Model-estimated relative risk of death 
based on the SARS-CoV-2 epidemic in 
France [15]
 
  Age 30-39 years   Reference category  
( =0.0006) 
Model-estimated based on fitting the 
SARS-CoV-2 epidemic in France [15]
 
  Age 40-49 years 3RRD   3 3.00RRD =  Model-estimated relative risk of death 
based on the SARS-CoV-2 epidemic in 
France [15]
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  Age 50-59 years 4RRD   4 10.00RRD =  Model-estimated relative risk of death 
based on the SARS-CoV-2 epidemic in 
France [15] 
  Age 60-69 years 5RRD   5 45.00RRD =  Model-estimated relative risk of death 
based on the SARS-CoV-2 epidemic in 
France [15] 
  Age 70-79 years 6RRD   6 120.00RRD =  Model-estimated relative risk of death 
based on the SARS-CoV-2 epidemic in 
France [15] 
 7RRD   7 505.00RRD =  Model-estimated relative risk of death 
based on the SARS-CoV-2 epidemic in 
France [15] 
Overall infectious 
contact rate  
  0.33 contacts per day Chosen to yield the desired value of 
0 1.2R =  in the US
 
  0.28 contacts per day Chosen to yield the desired value of 
0 1.0R =  in China 
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Figure S4. Impact of SARS-CoV-2 vaccination on numbers of A) new infections, B) new 
severe disease cases, C) new critical disease cases, and D) new deaths in the United States. 
The vaccine is assumed to have no efficacy against infection, but an efficacy of 95% against 
severe and critical disease. It is introduced on January 1, 2021, when the cumulative proportion 
of the population infected is 20%. Vaccine coverage is scaled up to reach 80% by December 31, 
2021. The duration of both vaccine protection and natural immunity is one year. This scenario 
assumes an 
0R  of 1.2 on January 1, 2021, which increases with gradual easing of restrictions to 
reach 4.0 after six months. 
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Figure S5. Impact of SARS-CoV-2 vaccination on numbers of A) new infections, B) new 
severe disease cases, C) new critical disease cases, and D) new deaths in China. The vaccine 
is assumed to have no efficacy against infection, but an efficacy of 95% against severe and 
critical disease and is introduced on January 1, 2021. Vaccine coverage is scaled up to reach 80% 
by December 31, 2021. The duration of both vaccine protection and natural immunity is one 
year. This scenario assumes an 
0R  of 1.0 on January 1, 2021, which increases with the gradual 
easing of restrictions to reach 4.0 after six months. 
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Figure S6. Impact of vaccine scale-up duration and vaccine coverage on numbers of 
averted severe and critical disease cases for a vaccine that protects only against disease. 
Cumulative numbers of averted severe and critical disease cases in A) the United States and C) 
China at different vaccination scale-up intervals to reach 80% coverage. Cumulative numbers of 
averted severe and critical disease cases in B) the United States and D) China at varying levels of 
vaccine coverage. The vaccine is assumed to have no efficacy against infection, but an efficacy 
of 95% against severe and critical disease and is introduced on January 1, 2021, when the 
cumulative proportion of the population infected is 20% in the United States and 0% in China. 
The duration of both vaccine protection and natural immunity is one year. This scenario assumes 
a gradual easing of restrictions within 6 months. 
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Figure S7. Impact of vaccine scale-up duration on the number of vaccinations needed to 
avert one infection (A), one severe disease case (B), one critical disease case (C), and one 
death (D) in China. The vaccine is assumed to have an efficacy of 95% against infection and is 
introduced on January 1, 2021, when the cumulative proportion of the population infected is 0%. 
The duration of both vaccine protection and natural immunity is one year. This scenario assumes 
a gradual easing of restrictions within 6 months. 
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Figure S8. Comparison of the impact of a vaccine acting against infection (VES efficacy) 
versus a vaccine acting only against disease (VEP efficacy) in China. The number of 
vaccinations needed to avert one severe disease case (A), one critical disease case (B), and one 
death (C), for a vaccine with 95%SVE =  versus a vaccine with 95%PVE = . The vaccine is 
introduced on January 1, 2021, when the cumulative proportion of the population infected is 0%. 
The duration of both vaccine protection and natural immunity is one year. This scenario assumes 
a gradual easing of restrictions within 6 months.  
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Figure S9. Impact of the duration of easing social and physical distancing restrictions on 
the number of averted severe and critical disease cases. The cumulative number of averted 
severe and critical disease cases in A) the United States and B) China at different durations of 
easing of restrictions. The vaccine is assumed to have an efficacy of 95% against infection and is 
introduced on January 1, 2021, when the cumulative proportion of the population infected is 20% 
in the United States and 0% in China. The duration of both vaccine protection and natural 
immunity is one year.  
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Figure S10. Uncertainty analyses. Numbers of new severe and critical disease cases in the 
United States assuming A) a vaccine that protects against both infection and disease and B) a 
vaccine that protects only against disease. Numbers of new severe and critical disease cases in 
China assuming C) a vaccine that protects against both infection and disease and D) a vaccine 
that protects only against disease. These scenarios assume gradual easing of restrictions within 6 
months. Shaded areas are the results of the 500 uncertainty runs, while the solid line is the mean 
of those runs. 
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